Abstract
In our efforts to find new whitening agent from natural resources, we focused on wood of Artocarpus heterophyllus which shows anti-melanogenesis activity. By activity-guided fractionation of A. heterophyllus wood extract, norartocarpetin (1) and artocarpesin (2) were isolated. These compounds have 4-substituted resorcinol moiety in B ring, which is an important substructure for revealing the tyrosinase inhibitory activity. Also, the effect of albanin A (3) which has 4-substituted resorcinol moiety at B ring with prenyl substituent at C-3 position, was examined for comparison. The IC50 values of mushroom tyrosinase inhibitory activity of norartocarpetin (1), artocarpesin (2) and albanin A (3) were 1.7, 8.5 and 463 μM, respectively. In melanin formation inhibition on B16 melanoma cells, the IC50 of these compounds (1-3) were 209.1, 45.1 and 40.1 μM, respectively. The roles of each substructure of flavones having 4-substituted resorcinol moiety with or without prenyl substituent on tyrosinase and melanin biosynthesis in B16 melanoma cells were discussed.
Keywords: Artocarpus heterophyllus, Tyrosinase, Melanin, 4-substituted resorcinol moiety, Prenyl substituents, B16 melanoma cells, Structure-activity relationship
Letters in Drug Design & Discovery
Title: Melanin Biosynthesis Inhibitors from Wood of Artocarpus heterophyllus: The Effect of Isoprenoid Substituent of Flavone with 4-Substituted Resorcinol Moiety at B Ring
Volume: 7 Issue: 8
Author(s): Enos T. Arung, Kuniyoshi Shimizu, Hiroyuki Tanaka and Ryuichiro Kondo
Affiliation:
Keywords: Artocarpus heterophyllus, Tyrosinase, Melanin, 4-substituted resorcinol moiety, Prenyl substituents, B16 melanoma cells, Structure-activity relationship
Abstract: In our efforts to find new whitening agent from natural resources, we focused on wood of Artocarpus heterophyllus which shows anti-melanogenesis activity. By activity-guided fractionation of A. heterophyllus wood extract, norartocarpetin (1) and artocarpesin (2) were isolated. These compounds have 4-substituted resorcinol moiety in B ring, which is an important substructure for revealing the tyrosinase inhibitory activity. Also, the effect of albanin A (3) which has 4-substituted resorcinol moiety at B ring with prenyl substituent at C-3 position, was examined for comparison. The IC50 values of mushroom tyrosinase inhibitory activity of norartocarpetin (1), artocarpesin (2) and albanin A (3) were 1.7, 8.5 and 463 μM, respectively. In melanin formation inhibition on B16 melanoma cells, the IC50 of these compounds (1-3) were 209.1, 45.1 and 40.1 μM, respectively. The roles of each substructure of flavones having 4-substituted resorcinol moiety with or without prenyl substituent on tyrosinase and melanin biosynthesis in B16 melanoma cells were discussed.
Export Options
About this article
Cite this article as:
T. Arung Enos, Shimizu Kuniyoshi, Tanaka Hiroyuki and Kondo Ryuichiro, Melanin Biosynthesis Inhibitors from Wood of Artocarpus heterophyllus: The Effect of Isoprenoid Substituent of Flavone with 4-Substituted Resorcinol Moiety at B Ring, Letters in Drug Design & Discovery 2010; 7 (8) . https://dx.doi.org/10.2174/157018010792062777
DOI https://dx.doi.org/10.2174/157018010792062777 |
Print ISSN 1570-1808 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-628X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Reactive Oxygen Species in Cancer Biology and Anticancer Therapy
Current Medicinal Chemistry Sorafenib (BAY 43-9006) in Hepatocellular Carcinoma Patients: From Discovery to Clinical Development
Current Medicinal Chemistry Molecular Evidence of Cryptotanshinone for Treatment and Prevention of Human Cancer
Anti-Cancer Agents in Medicinal Chemistry Betulin-Betulinic Acid Natural Product Based Analogs as Anti-Cancer Agents
Anti-Cancer Agents in Medicinal Chemistry Application of Resveratrol in Diabetes: Rationale, Strategies and Challenges
Current Molecular Medicine The Role of Emerging Genomics and Proteomics Technologies in Cancer Drug Target Discovery
Current Cancer Drug Targets Natural Compounds with Cell Growth Inhibitory Activity in Human Tumor Cell Lines
Anti-Cancer Agents in Medicinal Chemistry Advances in Nanomedicine Towards Clinical Application in Oncology and Immunology
Current Pharmaceutical Biotechnology Dedication of the Third Issue of ‘Current Alzheimer Research’ to President Ronald Reagan (1911-2004)
Current Alzheimer Research IDO and Clinical Conditions Associated with Depressive Symptoms
Current Drug Metabolism Multiple Functions of Generic Drugs: Future Perspectives of Aureolic Acid Group of Anti-Cancer Antibiotics and Non-Steroidal Anti-Inflammatory Drugs
Mini-Reviews in Medicinal Chemistry Anticancer Drug-Induced Immunomodulation and Cancer Therapeutics
Current Cancer Therapy Reviews <i>In Vitro</i> Validation of Camphene as a Potential Antiviral Agent Against Betanodavirus Causing Viral Nervous Necrosis in Barramundi
Anti-Infective Agents High-component Reactions (HCRs): An Overview of MCRs Containing Seven or More Components as Versatile Tools in Organic Synthesis
Current Organic Synthesis Leveraging Cell Cycle Analysis in Anticancer Drug Discovery to Identify Novel Plasmodial Drug Targets
Infectious Disorders - Drug Targets Deubiquitinating Enzymes as Therapeutic Targets in Cancer
Current Pharmaceutical Design Targeted Ultrasound Imaging of Cancer: An Emerging Technology on its Way to Clinics
Current Pharmaceutical Design Stem Cell Patents: An Innovative Approach to Anti-Cancer Drug Discovery
Recent Patents on Anti-Cancer Drug Discovery Bombesin-like Peptides: Candidates as Diagnostic and Therapeutic Tools
Current Pharmaceutical Design Targeting Cancer Stem Cell Lines as a New Treatment of Human Cancer
Recent Patents on Anti-Cancer Drug Discovery